Tyra Biosciences, Inc. (TYRA): Price and Financial Metrics
TYRA Price/Volume Stats
| Current price | $14.98 | 52-week high | $20.67 |
| Prev. close | $14.66 | 52-week low | $10.38 |
| Day low | $14.35 | Volume | 216,071 |
| Day high | $14.99 | Avg. volume | 132,300 |
| 50-day MA | $17.74 | Dividend yield | N/A |
| 200-day MA | $14.80 | Market Cap | 786.76M |
TYRA Stock Price Chart Interactive Chart >
Tyra Biosciences, Inc. (TYRA) Company Bio
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest TYRA News From Around the Web
Below are the latest news stories about TYRA BIOSCIENCES INC that investors may wish to consider to help them evaluate TYRA as an investment opportunity.
Tyra Biosciences to Participate in 2023 Jefferies London Healthcare ConferenceTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the 2023 Jefferies London Healthcare Conference, taking place November 14-16, 2023. |
Tyra Biosciences Reports Third Quarter 2023 Financial Results and HighlightsTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2023 and highlighted recent corporate progress. |
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual MeetingsTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings. |
We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare ConferenceTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate at the 2023 Cantor Global Healthcare Conference, taking place September 26-28, 2023, in New York, NY. |
TYRA Price Returns
| 1-mo | -13.76% |
| 3-mo | 14.09% |
| 6-mo | 6.62% |
| 1-year | -1.96% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 8.16% |
| 2023 | 82.24% |
| 2022 | -45.98% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...